BIF adds Mars Bioimaging to its investment portfolio

23 August 2024 Booster Innovation Fund adds Mars Bioimaging to its investment portfolio Booster is pleased to announce the addition of Mars Bioimaging (MBI) to the Booster Innovation Fund (BIF) portfolio. MBI operates in the medical diagnostics part of the life sciences and medical technologies sector. It specialises in spectral molecular imaging combining multiple imaging modalities to advance point-of-care diagnosis. MBI was formed in 2007, and is classified as expansion stage, with its technology origins being from University of Canterbury and CERN. BIF will make an initial cash investment of $75,000 of its $400,000 to be committed across multiple tranches. Following this initial transaction (and issue of additional units to fund the purchase), MBI will initially represent 0.4% of BIF’s investment portfolio of 33 active companies, and with a net asset value of over $19.7M. Investors can continue to purchase units in BIF on the NZX or can subscribe for units in the fund as part of the process described in the fund’s Product Disclosure Statement (PDS) that is available at www.booster.co.nz. For further information regarding BIF visit https://www.booster.co.nz/booster-investments/booster-innovation-fund.aspx For more information, please contact: Gary Scott Company Secretary Booster Investment Management Limited 04 8944300 About Booster Booster Investment Management Limited (Booster) is the manager and issuer of the Fund, and part of the Booster Group which has been helping New Zealanders save since 1998. The group currently administers superannuation and investment funds of over $6 billion on behalf of more than 190,000 New Zealanders. BIF is a managed investment fund that invests in early-stage companies founded on intellectual property originated or developed in New Zealand. For more information, including a copy of the Product Disclosure Statement, please visit www.booster.co.nz